Free Trial
NASDAQ:CMMB

Chemomab Therapeutics Q4 2023 Earnings Report

Chemomab Therapeutics logo
$1.36 +0.01 (+0.37%)
Closing price 05/23/2025 03:59 PM Eastern
Extended Trading
$1.42 +0.05 (+4.03%)
As of 05/23/2025 07:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Chemomab Therapeutics EPS Results

Actual EPS
-$0.26
Consensus EPS
-$0.40
Beat/Miss
Beat by +$0.14
One Year Ago EPS
-$0.72

Chemomab Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Chemomab Therapeutics Announcement Details

Quarter
Q4 2023
Time
Before Market Opens
Conference Call Date
Thursday, March 7, 2024
Conference Call Time
7:00AM ET

Chemomab Therapeutics Earnings Headlines

This Is The Moment You Betray Trump (Or Prove Them Wrong)
They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to Trump’s economic plan. But now there’s a way to protect your retirement without backing down. This free 2025 Wealth Protection Guide reveals how you can use a legal IRS loophole—nicknamed “Piggy Bank”—to shield your savings.
Chemomab Hikes on Q1 Figures
See More Chemomab Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Chemomab Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Chemomab Therapeutics and other key companies, straight to your email.

About Chemomab Therapeutics

Chemomab Therapeutics (NASDAQ:CMMB), a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

View Chemomab Therapeutics Profile

More Earnings Resources from MarketBeat